Novo Nordisk Partners With Metaphore Biotechnologies on New Obesity Drugs
Provided by
Dow Jones
By Helena Smolak
Ozempic maker Novo Nordisk signed a research collaboration with U.S. biotech company Metaphore Biotechnologies to develop up to two advanced obesity treatments, which could cost the company up to $600 million.
Metaphore Biotechnologies said on Thursday that the Danish drug company, which makes weight-loss drugs Ozempic and Wegovy, will use Metaphore's tech platform, which combines machine learning with molecular mimicry, to develop the treatments.
This is the third research and development deal with Metaphore Biotechnologies' parent company Flagship Pioneering.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
May 09, 2024 10:30 ET (14:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now